ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 26

Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies

Keiji Miura1, Ayako Kondo2, Kazuo Takahashi2, Daisuke Hirano2, Yoshiyuki Hiki3, Shunji Yoshida2, Yukio Yuzawa2 and Yoshikazu Kurosawa3, 1Institute for Comprehensive Medical Science, Fujita Health Universtiy, Toyoake, Japan, 2Fujita Health Universtiy School of Medicine, Toyoake, Japan, 3Fujita Health Universtiy, Toyoake, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, autoantigens and lupus nephritis, Enzyme-Linked Immunoabsorbant Assays (ELISA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B cell Function and Targeting in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose: Sera from patients with systemic vasculitis or inflammatory conditions have been reported to contain antibodies that bind to endothelial cells (EC), i.e., AECA (anti-endothelial cell antibodies). AECA are known to play immunogenic effects by triggering EC activation and vascular damage, but the immunopathological role of AECA is not clear. SDS-PAGE and Western blotting have previously been used for detecting target antigens of AECA. However, we assumed that these methods are not appropriate for searching genuine target antigens on cell surface, and developed a novel solubilized cell surface protein-capture ELISA (CSP-ELISA).

Methods: Antigens were obtained as cell surface proteins from the plasma membrane of human umbilical vein endothelial cells (HUVEC); these cell surface proteins were biotinylated, solubilized with detergent, and captured on ELISA wells coated with NeutrAvidin biotin binding protein. AECA titers in serum from 126 autoimmune disease patients and 122 healthy controls (HC) were tested. Additionally, sera from 52 patients with biopsy-proven lupus nephritis (LN), 25 with systemic lupus erythematosus (SLE) without renal involvement (non-LN SLE), 10 disease controls (DC) and 81 healthy controls were tested for IgG- and IgA-AECA to human glomerular EC (HGEC) by CSP-ELISA.

Results: IgG-AECA were detected in 28 of 36 (78%) of SLE patients; in 13 of 16 (81%) of mixed connective tissue disease (MCTD) patients; in 5 of 9 (56%) of systemic sclerosis (SSc); and in 4 of 122 (3%) of healthy controls. Relatively weak denaturation of antigens on ELISA wells caused loss of binding of these autoantibodies. Titers of IgG- and IgA- AECA to HGEC were significantly higher in LN and non-LN SLE patients than in the combined DC and HC (P < 0.001) groups. The level of IgG-AECA did not correlate with active lesions, but the level of IgA-AECA to HGEC did correlate with histological evidence of active lesions in LN patients (P < 0.001). Immunocytochemical analysis showed AECA recognized membrane proteins on HGEC. The significant correlation of titer of AECA to both HGEC and HUVEC (R = 0.95 for IgG-, 0.93 for IgA-AECA, respectively) indicated AECA in LN patients recognize membrane proteins expressed on HGEC and HUVEC. To identify specific antigens against AECA, biotinylated CSPs were incubated with sera from LN patients with high titers of IgG-AECA, immunoprecipitated with immobilized protein G followed by immobilized avidin, and blotted with NeutrAvidin. A 150-kDa protein band that shifted to a 55-kDa protein band under reducing conditions was detected in patients with LN, but not in HC.

Conclusion: This newly developed CSP-ELISA method enables the detection of antibodies to the labile epitopes of autoantigens such as membrane proteins, and this method is generally applicable to various kinds of membrane proteins and the antibodies against them. IgA-AECA was observed to be associated with pathological activity in LN. These EC membrane components recognized by AECA may be linked with the pathogenesis of LN. We propose CSP-ELISA for measuring AECA in serum samples for routine laboratory testing.


Disclosure:

K. Miura,
None;

A. Kondo,
None;

K. Takahashi,
None;

D. Hirano,
None;

Y. Hiki,
None;

S. Yoshida,
None;

Y. Yuzawa,
None;

Y. Kurosawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantibodies-directed-against-cell-surface-components-in-autoimmune-disease-patients-proposal-of-a-novel-elisa-for-the-detection-of-anti-endothelial-cell-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology